Letters to the Editor

SERTRALINE DOSING IN DEPRESSED INPATIENTS T o the Editor:
In a ret ro sp ective cha rt review of a ll psychi atric inpa t ie n ts, a t th e U niversity of T ex as H arris Cou n ty Psychi atric Cen te r, 2+ pati ent s were sta rted on se rt rali ne for tr ea t m en t of th e ir d epressive sym p to ms . The primary qu esti on to be a nswe re d by thi s cas e st ud y was th e dos e a t whi ch th e m aj orit y of inpatient s resp ond to se rt ra line in a clinical se tt ing . There a re no known reports conce rn ing th e d ose a t whi ch most inpati ent s resp ond .
Pati ents wer e not included in thi s st udy unl es s se rtra line wa s p rescrib ed as recomm ended by th e manufacturer (Pfize r), i.e. , an initia l dos e of 50 m g with a weekl y increa se of 50 mg if clinica lly indi cat ed , up to a m aximum of 200 m g. Ther e wer e 2+ patient s ( 18 wo men , 6 men) with a m ean age of 35 .2 yea rs (range 17-58) . Twenty pati ent s had a di a gn osis of m ajor d epressive di sorder, 10 of wh om had co nco m ita n t psych otic sym p to ms . Three pa t ients had a di a gn osis of schi zophren ia or sc h izoa ffec t ive di sorder, a nd a no ther had bipo lar d iso rd er, d epressed ph a se. In a dd ition to each patient rece iving se r t ra line , 16 of th e pat ien ts re ceived neu rol eptics and 20 were treat ed with ben zodi azepin es,
Of th e 2+ pati ent s, 2 1 were treat ed wit h se rt ra line for g rea te r th a n 5 days. Of these 21, 10 (+8%) res ponde d a t the initial 50 m g d a ily dose, 8 (38 %) a t 100 m g dai ly, 2 ( 10%) a t 150 mg daily, a nd I (5%) a t 200 m g d a ily. A resp on se was d efin ed as a sig nifican t im p rove m e n t in th e de p ress ion suc h tha t th e pat ient co uld be d ischarged fro m th e hospit al. No rati ng scale s were used . O ne patient was tak e n off se rt ra line a fte r I d ay a nd a not her aft e r 5 days for wor sening m edi cal or psychi atric proble m s, wh ich we re not fe lt to be re la ted to sert ra lin e. A third patient had se r t ra line di scontinued on d ay 5 fo r ur inary a nd fecal incon tine nce , whi ch was fclt to be a side effect. Of th e 2 1 pati ents who were di sch a rged on ser t ra line, 3 com pla ine d of sid e e ffec ts wh ich included mild di zziness, mild to mod e ra t e nau sea an d occasiona l d ry mo uth. Fift ee n cha r ts had document ation indicating no side effects ; 3 char ts ha d no docu m en ta tion reg arding side effects .
In this retrospecti ve review , +8% of d epressed inpati ent s resp onded a t th e initial 50 mg d ail y dose, a nd 86% resp onded at 100 m g o r less. Thompson e t a l in a co ntro lled d ose esca la t ion st udy report ed 59% of d epres sed o u t pa tie n ts responded a t th e initial 50 mg sert ra line dos e (I ). Doo gan a nd C a illa rd (2) in a sim ila r d esign report ed th at 78% of d epressed ou t pa ti en ts im proved on a m ean sertraline dos e of less th an 100 m g da ily. Optimum dose is best eva lua ted in a fixed dos e trial, sinc e dos e esca la t io n st ud ies usually favor high er d oses as m ost effect ive. T o dat e, th ere have be en no co nt ro lled fixed do se trials with se rt ra line . Our curren t result s using a do se esca la ting regimen mu st be viewed with ca u t ion for this reason as well as others. The retrosp ective nature of this review a s well a s the mix ed diagn osti c gro u ps, co nco m itt a n t m edi cation use, va ria ble len gth o f hospit aliz ation a nd lack of sta nda rd ized a ssessme n t of d epressive sym p to ms are clear lim ita t io ns of this rep or t. Further, t he apparent h igh response rat e in our su bjects a nd relatively benign side effec t pr ofile ma y be du e to lim ited cha rt document a ti on o f opt imal ben e fits a nd d raw ba cks of me d ica t ion . Nonetheless, this a nec do ta l W e wis h to rep ort a cas e of tardive dyskinesia th at has shown a rapid a nd d ra mat ic respo nse to C loza pine without incid ent of ser ious side effec ts.
Case Report : A.S. is a n 80 yea r-old, widowed , white fem al e who had ca r ried a di agn osis of ch ro nic sch izo ph re nia since 1964 and had sin ce th en tak en T ril afon , 8 m g b.i.d . wit h satisfactory th erapeutic results.
As ea rly as 5 years prior to ad m ission, A.S. was see n to have probl em s with "blin king of her eyes." Examination sho wed a left facial hemispasm th at would persist for seve ra l seconds duration, som etimes up to 30 seconds . This was accom pa nied by a fine twitching abo ut bot h eye lids a nd both sid es of her mouth. Approxim at ely 3 months pr ior to admission, she was seen in clinic for un controllabl e eye blinking th at had worsen ed in th e preced in g 7 mon th s. No signs of lip sm acking, tongu e rolling, or pill ro lling m ovements were no tic ed by her d oct or. H e r family had noticed a sligh t trem or bil at erall y in her upper ex t re m ities in addi t ion to he r facial movem en ts . A pr eliminary diagnosis of tardive dyskinesia was esta blished a nd her T rilafon was su bse q ue n tly reduced to 4 mg b.i .d .. Sh e wa s see n aga in three week s lat e r withou t subsequ en t improvem ent , a nd her med ication s were di scontinued. Her fam ily re port ed t hat her a ud itory hallucin ation s th en markedl y wor sen ed , a nd he r th ou ght beca m e ex t re me ly incoheren t. O ne month lat er, she was again re-ex amined a nd found to have wors ening of he r eye blinking a nd facial grimacing. Sh e was th en a d m itted to a psychi atric uni t for eva lua t ion and a lte rnat ive psychotropic th erapy.
*Two of th e above a ut hors (DW, C P) hold sto ck in Pfizer Ph armaceutical s.
Ex amination up on ad m ission reve a led per sist ent ab no r ma l invo lunt ary movem ent s. These co nsis te d of exagge ra te d eye blinki ng bil at e rally, unusua l ex t re me g rimacing, jaw cle nching , occ ur ring a t a frequ en cy of a pproxim a t e ly on ce per second , and variou s lin g ual m ovem ents. A pill rolling tremor was a lso not ed in th e a bsence of other truncal a nd upper/lower limb ex t re m ity movements . A DISC US assessme n t a t that time reveal ed a sco re of25.
On day 6 of ad m issio n, she was star te d on clozapi ne, 25 m g b.i.d . Th e dose was su bse q ue n tly rai sed to 25 m g t.i .d. on d ay 7. H er signs of ta rd ive dyskinesia showed a su bseq uent dr a ma tic and ra pid imp rove m ent in response to this medi cation . She was eval ua te d with th e DI SC US on d ay II whi ch revealed a score of 16. Th rough out th e remainde r of her stay, facial movem ents persist ed , a lt ho ug h to a lesser degree th an upon ad m ission, a nd she was su bsequ en tly d ischarge d on day 12 on clozapine, 25 mg b.i.d.
On follow-up 4 week s lat er, she was se en to have co nt in uing involunt ary movem ents. A DI SC US assess me nt reveal ed a score of 13, with gri macing a nd blin king rem aining severe. Auditory hallu cin ation s co nt in ue d, bu t to a lesser degree. Throughout her Cl ozapine tri al , wee kly hemato log ic m o ni torin g rev ea led no signs of neut ropen ia .
D iscussion: Cu rr ent es t ima tes of th e pr eval en ce of TO a mo ng pat ien ts tak ing neurolep tic dru gs is tho ug h t to be 20%; however, ra tes va ry amo ng pa ti e nt pop ulations, ce rtain subg ro ups of e lde rly excee ding 50% ( 1,2,3). Co nve n tio na l neu rol e ptics hav e a ll been implicat ed in ca us ing dru g-induced movem ent d isorders (1,3,4), which a re th ou ght to result fro m a ltered doparnine rg ic ac t ivity within th e basal ga ng lia (5) .
T his pat ient de m on strat ed a rapid a nd dra ma tic response to clozapine, her D ISC US score dropping fro m 25 to 16 within II d ays, a nd to 13 within one mo nt h. Most of th e immediat e im prove me n t was seen in reducti on of o ra l a nd lin gu al movements; unfort una t ely, facial an d eye movemen ts co nti nued to re main seve re. T he re was no wor sening in a ny of th e DISC US sca le it em s a t one month co m pared to her initi al exam.
Lieb erm a n , e t a l. (3) sugges ts seve ra l possibl e ex pla na t ions for th e effec t ive ness of clozapine in patie nts with TO. There m a y exist a suppressive (maskin g) effect, suc h as th at see n with " classica l" neu roleptics. H oweve r , th er e may be a g rad ua l improvem ent in reversibl e TO in th e abse nce of a n agent th at prom ot es TO. There m ay a lso exist a specific t he ra peu tic effect in whi ch clozapi ne ac tively reduces symptoms of T O. T his patient 's rapid resp on se suggests t ha t she ben efit ed from a n acu te su ppressive effec t ; how ever, either of th e two re maining mech anism s may st ill account for patient 's lon g term improve me nt wit h clozapine. Dat a from clinical tri al s sugges t th at a p proximately 43% of patients wit h T O , particularly th ose wit h dyst oni c featu res, sho w im prove men t (50% or greater reduct ion in TO sym pto ms) afte r t rea t me n t with clozapine.
C ur re nt ly, no sa t isfacto ry t reatme nt ex ists for irr eve rsibl e ta rdive dys kin esia , a ltho ug h some case s do a ppear to be reversible if detected ea rly enoug h. Therefore, cur re nt treat ment is focuse d on prevention , th e ph ysician havin g a n obliga tion to decr ease th e dosage of neurolept ic th erapy without co m prom ising psychi atric be nefit. For th ose pa tien ts who do deve lop TD , seve ra l t he ra pe u tic s tra tegies have bee n proposed, but have subsequ ent ly pr oved to be di sappoint in g ( I) . Reducti on or di scont inu ation of neurol ept ic t herapy is usually recommended , but difficult du e to br eakthrou gh of psychi atric sym ptoms ( 1,2); prolonged th er apy usu ally aggrava tes TO to th e point wh er e it may eve n tua lly become life-t hrea te ning for th e pa ti ent.
Perhaps a ll pat ients ca pa ble of tolerating clozapine, wh o show pr ob abl e or d efinite signs of TO , sho uld ro ut inely receive a tri al of clozapine. Serious side effects ma y cont ribute to a ph ysicians re luc ta nce to initiat e clozapin e t he rapy with such patients ; how ever, rout ine
